Product image of Jansitin (Sitagliptin) supplied by GNH India

Jansitin

Active Ingredient:
Sitagliptin
Origin:
EU

Jansitin (Sitagliptin)

Sitagliptin, the active ingredient in Jansitin, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to lower blood glucose levels when used with diet and exercise.
GNH India supplies Jansitin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jansitin (sitagliptin) is used within the DPP‑4 inhibitor class to manage hyperglycaemia in type 2 diabetes.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose when combined with diet and exercise.
  • Inadequate control with metformin alone: provides additional HbA1c reduction as monotherapy.
  • Combination therapy with other antidiabetic agents: enhances overall glycaemic control in patients requiring multi‑drug regimens.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion and suppress glucagon release, resulting in improved post‑prandial glucose regulation without causing hypoglycaemia in the absence of other insulin‑secretagogues.

Side Effects

Adverse reactions to sitagliptin may vary in frequency and severity.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory infection symptoms.
  • Headache: transient mild to moderate pain.
  • Upper respiratory tract infection: cough, sore throat.
  • Dizziness: occasional light‑headedness.
  • Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Joint pain: unexplained arthralgia.
  • Bullous pemphigoid: rare blistering skin disorder.
  • Hypersensitivity: fever, eosinophilia, or organ involvement.

Precautions & Warnings

Before initiating sitagliptin therapy, consider the following safety measures.

  • Renal impairment: adjust dose or avoid in severe renal dysfunction.
  • Hepatic impairment: use with caution in moderate liver disease.
  • Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas.
  • Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; dose adjustments may be needed.
  • Cardiovascular disease: no specific contraindication, but monitor overall risk profile.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Sitagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: may cause severe hypoglycaemia; dose reduction required.
  • Strong DPP‑4 inhibitors (e.g., saxagliptin): additive effect increases risk of adverse events.

Moderate Interactions (Monitor Closely)

  • Rifampin: induces metabolism, potentially reducing sitagliptin exposure.
  • Digoxin: may increase digoxin levels; monitor serum concentrations.
  • Diuretics (e.g., thiazides): may enhance hypoglycaemic effect; observe blood glucose closely.

Frequently Asked Questions

Jansitin contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels when used together with diet, exercise, and other antidiabetic medications as prescribed by a healthcare professional.

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition increases the levels of the incretin hormones GLP‑1 and GIP, which enhance glucose‑dependent insulin secretion and suppress glucagon release, thereby improving glycaemic control.

The dose of Jansitin is determined by the prescribing clinician based on the individual’s renal function, glycaemic targets, and concomitant therapies. Patients should follow the exact dosing instructions provided by their healthcare professional.

The safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the prescribing physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other oral antidiabetics such as sulfonylureas or metformin, sitagliptin offers glucose‑dependent insulin secretion with a lower risk of hypoglycaemia when used alone. It is often added to existing regimens to achieve additional HbA1c reduction without significant weight gain.

Jansitin tablets should be stored below 25 °C in their original container, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use it after the expiry date.

Jansitin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse events linked to sitagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or swelling.

Jansitin is contraindicated in patients with a known hypersensitivity to sitagliptin or any of its excipients. It should also be avoided in individuals with severe renal impairment unless dose‑adjusted by a physician, and caution is advised in those with a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT